GlassScriptPhysician profile
Morey A Blinder
NPI 1215953526
$234,986.02
in general payments reported to CMS, 2019-2025
30 companies · $22K in 2025
The $22K reported for 2025 was more than what 84% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $19K · 2021: $9,511 · 2022: $38K · 2023: $28K · 2024: $41K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $64K · Honoraria: $14K · Travel and Lodging: $7,778 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,150 · Food and Beverage: $2,381 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $63,648.00 |
| Honoraria | $14,380.00 |
| Travel and Lodging | $7,777.54 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,150.00 |
| Food and Beverage | $2,380.51 |
| Education | $148.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $63,631.19 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $55,177.19 | 2019-2025 | |
| Agios Pharmaceuticals, INC. | $29,995.91 | 2020-2025 | Pyrukynd |
| Amgen INC. | $19,453.86 | 2019-2022 | |
| Sobi, INC | $10,941.11 | 2022-2025 | |
| Bioverativ Therapeutics INC. | $8,675.62 | 2019 | |
| Chiesi USA, INC. | $8,425.21 | 2023 | Ferriprox |
| Portola Pharmaceuticals, LLC | $8,295.21 | 2019 | |
| Recordati_rare_diseases_inc. | $7,096.57 | 2025 | Enjaymo |
| Pharmacosmos Therapeutics INC. | $6,505.54 | 2021-2025 | Monoferric |
| Global Blood Therapeutics, INC. | $3,850.00 | 2021 | |
| Beckman Coulter, INC. | $3,219.58 | 2021-2025 | Dxh 900 Hematology System |
| Alnylam Pharmaceuticals INC. | $2,760.00 | 2024 | Givlaari |
| Kedrion Biopharma INC. | $2,623.00 | 2019 | |
| Csl Behring | $2,356.68 | 2019-2024 | Hemgenix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,136.00 | 2024 | |
| Shire North American Group INC | $243.87 | 2019 | |
| Novo Nordisk INC | $174.54 | 2019-2025 | Alhemo |
| Genentech USA, INC. | $128.00 | 2019 | |
| Galderma Laboratories, L.P. | $125.16 | 2019 | |
| Glaxosmithkline, LLC. | $88.65 | 2025 | Ojjaara, Blenrep |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2021 | |
| Celgene Corporation | $20.82 | 2019 | |
| Pharmaessentia USA Corporation | $17.51 | 2025 | Besremi |
| Hema Biologics, LLC | $15.04 | 2025 | Sevenfact |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morey Blinder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.